Plexxikon Announces Encouraging Data From Phase 1 Extension Study Of PLX4032 Showing Objective Responses In Metastatic Melanoma Patients

Plexxikon Inc. announced encouraging clinical data from a Phase 1 extension study of PLX4032 (RG7204) in metastatic melanoma patients, which expand the results announced from the initial phase of the study. PLX4032 is a novel, oral and highly selective drug that targets the BRAFV600E cancer-causing mutation that occurs in about 50 percent of melanomas and about eight percent of all solid tumors.